NPC-15669

**NPC-15669** is a small molecule drug in the leumedin family, originally developed by Johnson & Johnson. It acts as a potent inhibitor of leukocyte recruitment by targeting the CD18 subunit (integrin subunit beta 2) of the Mac-1 (CD11b/CD18) integrin complex, thereby blocking neutrophil adhesion to vascular endothelium and preventing tissue infiltration and injury. NPC-15669 alters multiple neutrophil functions, including suppression of cell surface CD18 upregulation, scavenging of hypochlorous acid, and inhibition of agonist-stimulated degranulation (release of myeloperoxidase and elastase). Preclinical studies in swine and rat models have shown efficacy in reducing lung injury during cardiopulmonary bypass, diminishing inflammation in experimental colitis, and limiting infarct size during myocardial reperfusion injury. Its therapeutic areas explored included infectious disease, cardiovascular disease, and digestive system disorders. Development was discontinued after completion of Phase 1 clinical studies[1][3][4][7].

Brand names

NPC-15669NPC15669NPC 15669

Other names

N-[9H-(2,7-dimethylfluorenyl-9-methoxy)carbonyl]-L-leucineleumedin